Express News | Hainan Shuangcheng Pharmaceuticals will carefully consider future development strategies based on normal production and operation conditions, market environment, and related policies.

BreakingsMar 13 20:48

Express News | Hainan Shuangcheng Pharmaceuticals: An investor briefing will be held on March 13 to discuss the termination of issuing shares and paying cash for the purchase of Assets and raising matching funds and related Trade matters.

BreakingsMar 11 16:48

Shuangcheng Pharmaceuticals Scraps Plan to Acquire Aura Semiconductor Via Share Issuance

MT NewswiresMar 11 16:04

A-shares movement丨Hainan Shuangcheng Pharmaceuticals hits the maximum drop limit, and the failure of the restructuring raises the alarm for (Delisted).

On March 11, Glonghui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) hit its daily limit down, with current sealed order amounts exceeding 0.5 billion yuan, priced at 12.43 yuan, marking a new low since the end of September last year, with a total market value of 5.155 billion yuan. In news, Hainan Shuangcheng Pharmaceuticals suddenly announced late last night the termination of the acquisition of Airola Holdings, after planning this Trade last year, the stock price soared sevenfold in one instance, achieving '21 trading days in 23 days.' It is reported that the 25 trading partners faced significant differences in the cost of acquiring shares, and Institutions entering during Pre-IPO financing might face high cost pressures. Some analyses suggest that the company's Operation is poor, facing *ST risks, and the failed restructuring could push it further.

Gelonghui FinanceMar 11 11:40

The "king of monsters" in the A-shares has fallen: Hainan Shuangcheng Pharmaceuticals has terminated its restructuring late at night, potentially facing a delisting crisis.

The sky has fallen.

Gelonghui FinanceMar 11 11:05

The late-night announcement of the "Demon King" triggered a "Moment of Crisis" as Hainan Shuangcheng Pharmaceuticals' restructuring failure sounded the alarm for (Delisted).

1. Hainan Shuangcheng Pharmaceuticals suddenly announced at midnight that it would terminate the acquisition of Aola shares. After planning this Trade last year, the stock price once surged 7 times with "21 boards in 23 days"; 2. The cost differences of the equity obtained by the 25 counterparties faced by the company are significant, and the cost pressure for institutions that entered during Pre-IPO financing may be higher; 3. The company's operating situation is poor and is facing Special Treat, and the failed restructuring may push it into a more dangerous situation.

cls.cnMar 11 08:51